TY  - JOUR
AU  - Ludvik, Bernhard
AU  - Frías, Juan P
AU  - Tinahones, Francisco J
AU  - Wainstein, Julio
AU  - Jiang, Honghua
AU  - Robertson, Kenneth E
AU  - García-Pérez, Luis-Emilio
AU  - Woodward, D Bradley
AU  - Milicevic, Zvonko
PY  - 2018
DO  - 10.1016/S2213-8587(18)30023-8
UR  - http://hdl.handle.net/10668/12183
T2  - The lancet. Diabetes & endocrinology
AB  - Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors improve glycaemic control and reduce bodyweight in patients with type 2 diabetes through different mechanisms. We assessed the safety and efficacy...
LA  - en
KW  - Diabetes Mellitus, Type 2
KW  - Double-Blind Method
KW  - Drug Therapy, Combination
KW  - Female
KW  - Glucagon-Like Peptides
KW  - Glycated Hemoglobin
KW  - Humans
KW  - Hypoglycemic Agents
KW  - Immunoglobulin Fc Fragments
KW  - Male
KW  - Middle Aged
KW  - Recombinant Fusion Proteins
KW  - Sodium-Glucose Transporter 2 Inhibitors
KW  - Treatment Outcome
TI  - Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
TY  - research article
VL  - 6
ER  -